Many ocular disorders leading to blindness could benefit from efficient delivery of therapeutics to the retina. However, despite extensive research into drug delivery vehicles and administration techniques, efficacy remains limited because of the many static and dynamic barriers present in the eye. Comprehension of the various barriers and especially how to overcome them can improve our ability to estimate the potential of existent drug delivery vectors and support the design of new ones. To this end, this review gives an overview of the most important ocular barriers for each administration route to the back of the eye. For each barrier, its biological composition and its role as an obstacle towards macromolecules, nanoparticles and viral vectors will be discussed; special attention will be paid to the influence of size, charge and lipophilicity of drug(s) (carrier) on their ability to overcome each barrier. Finally, the most significant available in vitro and ex vivo methods and models to test the potential of a therapeutic to cross each barrier are listed.
Introduction
Today, blindness affects 180 million people worldwide. By 2020, it is estimated that the global prevalence of people suffering from blindness will expand to 200 million. Next to the tragic impact of vision loss on the lives and the surroundings of these people, the healthcare costs associated with blindness are extensive. In fact, the total global health care expenditure is predicted to rise up to $2.8 trillion by 2020 [1] . Many blinding pathologies find their origin in the retina, of which the most prevalent diseases include diabetic retinopathy, retinitis pigmentosa and age-related macular degeneration (AMD) [1] . Therefore, a vast amount of research in academia and industry is dedicated to the delivery of therapeutic entities (e.g. steroids, antibodies or genes) to the back of the eye. To this end a great variety of advanced drug delivery systems are being investigated and developed, such as intravitreal implants and nanoparticles. However, although the eye is an easily accessible organ, its many physiological and anatomical barriers still considerably restrict effective diffusion of therapeutics to the target site.
A detailed characterization of the obstacles drug delivery carriers have to overcome is essential to define the barrier role of a specific ocular tissue. This in its turn allows for smart adjustments to the drug delivery carriers in line with the barriers' properties. In vivo experiments are of great value to determine the overall efficiency of a drug delivery system with all barriers in place. In vitro and ex vivo studies, on the other hand, enable us to examine each barrier in the delivery process on its own, providing preliminary evidence of the ability of a delivery system to overcome this single barrier. Furthermore, ex vivo explant cultures allow us to experiment on ocular tissues of larger, more relevant species (e.g. pig, non-human primates or even human eyes) providing valuable information without proceeding to costly and labor-intensive in vivo work. The proper use of in vitro and ex vivo models can thus be a significant step forward in the design and optimization of therapeutics and their vehicles for ocular drug delivery.
Depending on the intended therapeutic compound and the desired site of action, several administration routes are available. For the posterior segment of the eye, an overview of possible administration routes is depicted in Fig. 1 . Even though some administration routes are clinically preferred over others, each route comes with its own advantages and set of obstacles to conquer [2] . In this review, we will discuss the biological structure of the barriers and biological obstacles encountered for each of these administration routes while linking drug (carrier) physicochemistry to successful barrier passage. Finally, we will give a summary of the most relevant in vitro and ex vivo methods that might be useful in research focusing on advanced drug delivery into the posterior segment of the eye.
Barrier composition and role

Barriers encountered after intravitreal injection
During intravitreal injection a drug formulation is injected into the vitreous humor of the eye (Fig. 1) . In the clinic, intravitreal injections happen on a daily basis for a plethora of drugs, with currently anti-VEGF (Vascular Edothelial Growth Factor) medication as the most routinely injected therapeutic against AMD. Delivering the therapeutics directly into the vitreous offers several benefits. Firstly, several anterior barriers are bypassed and the drug is delivered close to the target site. Secondly, the procedure is relatively easy and can be performed by trained personnel. Furthermore, intravitreal injection is considered very safe, with the most common complication being endophthalmitis with an overall incidence rate of only 0.03% [3, 4] . Given these advantages intravitreal injection is a widely investigated administration route for the delivery of an increasing variety of drug delivery systems, ranging from gene vectors to biodegradable implants [5] . Unfortunately, the intraocular location of the therapeutics is no guarantee for success since the therapeutic efficiency is known to be highly dependent on the therapeutics ability to migrate from the injection site towards the retina [6] . In this regard, there are two main obstacles that hamper successful therapy after intravitreal injection, i.e. the vitreous and the inner limiting membrane (ILM).
Vitreous
The vitreous body is a transparent gel-like structure with a volume of about 4 ml that occupies approximately 80% of the human eye. The function of the vitreous body is a recurring subject of discussion, but is mostly considered to regulate eye size during eye development [7] . Due to its extremely high water content (98%-99%), the density of the vitreous body approximates that of water [6, 8] . The gel structure is composed of a 3-dimensional network of collagen fibers of collagen types II, IX, and V/XI, with collagen type II being the most abundant (60-75%). These collagen fibers provide the vitreous with flexibility and strength against mechanical tensions [8] . The spaces in between these fibrils are filled with glycosaminoglycans (GAGs) of which hyaluronic acid (HA), a highly hydrated negatively charged GAG, represents the bulk (Fig. 2) . The function of this linear polymer is to stabilize the collagen net and to ensure a swelling effect [9] . The remaining fraction of GAGs is represented by chondroitin sulfate and heparin sulfate [10] . Interestingly, the composition of the vitreous is not uniform throughout the whole vitreous body but different anatomical regions can be identified. The largest volume is taken in by the central vitreous, which is characterized by a more liquid state owing to the low density of its collagen network. In contrast, the cortical vitreous, which delineates the retina, contains higher concentrations of collagen as well as HA providing it with high mechanical strength [8] . A well-described phenomenon that affects the structure of the vitreous humor is liquefaction. During this process, which is mostly induced by age, the vitreous degrades leading to a loss of its gel-like appearance and an increase of its free water content; both factors that can influence the barrier function of the vitreous [11] .
In general, two types of barriers can be differentiated within the vitreous: the anatomical or static barrier represented by the vitreous structure itself, and the physiological or dynamic barrier represented by the flow processes and clearance pathways taking place in the vitreous. The fact that the vitreous represents an anatomical barrier toward drug diffusion has already been discovered early on when Sakamoto et al. revealed that a vitrectomy significantly enhanced the transduction efficiency of viral vectors from the vitreous [12] . In the same line, also the penetration of non-viral vectors seems to be hindered by the vitreous gel structure [6] . In this case, it is reported that the particle surface characteristics are of great importance. A general trend can be recognized: positively charged nanomaterials are blocked in their diffusion by interaction with the negatively charged components of the vitreal network [13] [14] [15] [16] [17] [18] , while negatively charged particles, based on for example poly lactic-co-glycolic acid (PLGA) or human serum albumin, distribute successfully across the vitreous humor [18] [19] [20] [21] . Consequently, various strategies have been explored to shield the surfaces of cationic particles and thus prevent unwanted interactions with vitreal components. Several polymers have already been suggested, such as polyethyleneglycol (PEG) and HA, to coat positively charged nanomaterials and thus improve the migration of the particles through the vitreous [15, 22, 23] .
While nanoparticle charge evidently influences particle diffusion, the impact of particle size is less obvious. Xu et al. have estimated the average pore size of bovine vitreous to be~550 ± 50 nm and indeed witnessed that 1 μm sized particles were not able of maneuvering through the meshwork [17] . In contrast, Martens et al. observed that negatively charged particles up to 1 μm were mobile in bovine vitreous based on a similar model [14] . These studies suggest that the pore size is surely large enough for small molecules and antibodies to diffuse freely through the vitreal meshwork. In addition, since the nanoparticle size for ocular (gene) therapy usually varies from 10 to 500 nm, the vitreal network should not be a major obstacle. However, as will be discussed in Section 2.1.2, it is important to keep in mind when aiming for retinal targets that there is also a size limit for penetration through the ILM that probably lies lower.
Next to the anatomical barrier inherent to the vitreous structure, drug distribution is also influenced by physiological obstacles like clearance pathways and intraocular flow processes. The most important flow processes within the eye are the convective flows. These flows are driven by the pressure difference between the front and back side of the vitreous and are oriented in an anterior-posterior direction [24, 25] . While these flows have barely any effect on the distribution of small drugs with high diffusivity, they can have a substantial effect on larger, less diffusible therapeutics, especially in larger species such as humans [24] [25] [26] . The physicochemical characteristics of molecules/particles have a huge impact on the way they are cleared and thus influence their half-life in the eye. Smaller more lipophilic entities are usually cleared at the posterior side since these are easily able of crossing the blood-retina barrier, leading to short intravitreal half-lives of a couple of hours. Larger more hydrophilic therapeutics, on the other hand, are eliminated through the anterior route which is dominated by the aqueous humor outflow. These entities, for example antibodies, tend to remain within the vitreous for a longer time with half-lives reaching 100 h [27] . Next to the intrinsic flow processes taking place within the eye, drug distribution is likely also influenced by the vitreous humor motion associated with eye movement (i.e. saccadic movement). However, the impact of this motion on intravitreal drug delivery is hard to predict since its influence has until now mainly been studied in vitreous substitutes [28, 29] .
Inner limiting membrane
The ILM forms the structural boundary between the vitreous and the retina and is mainly composed of collagen type IV, laminin and fibronectin which form an intertwined network [30] . Essentially, this extracellular matrix (ECM) represents the basement membrane of the Müller cells and thus aligns with their endfeet (Fig. 2) [31] . There is strong evidence that the lens and ciliary body are the primary production sites for ILM proteins during embryogenesis [30, 32] . The ILM has proven essential for the early development of the eye, seeing its absence is associated with retinal abnormalities including an aberrant ganglion cell layer [33, 34] . In the fully developed eye, however, the ILM is likely not crucial since ILM peeling is not correlated with severe adverse effects [35] . Also, it was observed that the ILM of macaques is not regenerated even one year after its removal [36] .
Similar to the vitreous, the composition of the ILM is not consistent over the entire tissue but varies regionally. Also the thickness of the ILM differs per region, steadily increasing toward the posterior pole [31] . Another important fact is that the ILM varies greatly between different species. Transmission electron microscopy (TEM) data revealed that the ILM of an adult mouse is merely 100 nm thick while atomic force microscopy measurements proved that the ILM thickness of a human retina measures up to 4 μm [37, 38] . Furthermore, several research groups have shown that the ILM layer thickens with age [30, 39] . The thickness of the ILM undeniably influences its barrier function, where it is assumed that the barrier is more easily surmountable in smaller animals, such as mice, than in larger ones, like non-human primates and humans.
There are many reports on the physical barrier role of the ILM in context of non-viral and viral gene delivery to the retina. Intravitreal injection in vivo seldom leads to effective gene expression in larger animals than rodents, often because of the accumulation of the vectors at the ILM [40] [41] [42] [43] . In fact, Dalkara et al. elegantly demonstrated in rats that inducing mild enzymatic digestion of the ILM by protease treatment exceptionally enhanced the transfection efficiency of several adenoassociated virus serotypes (AAV) from the vitreous [44] . Similarly, when the ILM is breached due to retinal disease, viral transduction was greatly improved when compared to ILMs in a healthy state [45, 46] . Also Takahashi et al. witnessed that surgical ILM peeling substantially enhanced the transduction of the inner retina in cynomolgus monkeys [42] . Taken together, these observations convincingly substantiate the barrier role of the ILM for viral drug delivery to retinal targets. Remarkably, interaction of viral vectors with binding sites at the ILM (e.g. laminin receptor or heparin sulfate) might enhance their accumulation at the vitreoretinal interface, allowing the vectors to further diffuse into the retina and produce gene expression [44, 45, [47] [48] [49] . In fact, Boye et al. corroborated that heparin sulfate binding of the viral capsid to the ILM is essential for transduction from the vitreous [49] .
Several research groups have reported on the barrier role of the ILM toward non-viral particles, where a clear trend regarding particle charge is noticeable. Indeed, in rodent as well as bovine species positively charged nanoparticles are virtually entirely obstructed by the ILM while neutral to negatively charged ones do penetrate into the retina [16, 50] . Regarding particle size the trend is less apparent since the majority of studies has been performed on rodents. In this species, particles up to 350 nm penetrated into the retina, though it is not certain this observation can be extrapolated to larger species such as cow or human [16, 21, 51, 52] . Peculiarly, Bourges et al. detected that highly negative polylactide particles of~150 nm and neutral ones of~350 nm accumulated at the ILM 1 h after intravitreal injection followed by penetration into the rat retina [52] . This suggests that, similar to viral vectors, presence of binding sites in the ILM might facilitate the diffusion of carriers into the retina.
Also for macromolecules, the ILM reduces or even blocks retinal passage depending on the physicochemical properties of the molecule. While negatively charged 20 kDa sized dextrans passed the ILM smoothly, positively charged molecules of the same size were virtually all blocked by the ILM [50] . Since even negatively charged dextrans of 2000 kDa in size penetrated more efficiently into the bovine retina than 20 kDa positively charged molecules, it is obvious that charge surely represents the dominant factor defining passage of macromolecules through the ILM [50] .
Barriers encountered after subretinal injection
A subretinal injection is an injection right below the neural retina, in between the photoreceptor layer and the retinal pigment epithelium (RPE) layer (Fig. 1) [53, 54] . A typical volume of around 150 μl is injected, leading to a transient detachment between these two layers. Complications are relatively common and more severe when compared to e.g. intravitreal injection, as this retinal detachment can result in photoreceptor death and loss of vision. The procedure is quite invasive, as subretinal injection is usually preceded by full anesthesia and a vitrectomy [55] . Despite the drawbacks of this administration route, it is very effective to deliver therapeutics right at the target site. Subretinal injections are therefore mostly applied for larger entities such as gene vectors or cells that are therapeutically relatively ineffective using other administration routes [56] . As a matter of fact, subretinal injection is the most clinically investigated delivery route for retinal gene therapy with some successes yet reported [57, 58] . Since the injection site is so close to the retina, practically all barriers in the posterior segment are circumvented. Gene expression is however often limited to the injection site, suggesting that the primary barrier for efficient therapy following subretinal injection is the retina itself [59] .
Neural retina
The retina is the tissue at the back of the eye that receives light and transmits it to the brain where the signals are further processed into an image. It is constituted of a neatly organized multilayered structure that allows interplay between its photoreceptors, neurons and glial cells (Fig. 3) . The barrier role of the retina can be attributed to its dense structure which prevents free diffusion of (therapeutic) macromolecules. In light of this, Jackson et al. have observed that the retinal exclusion limit, i.e. the maximum molecule size able of freely diffusing through the retina, is dominantly defined by the inner and outer plexiform layer [60] . This limit is approximately 76 kDa for a fixed human retina, though since therapeutic antibodies such as bevacizumab (Mw 149 kDa) have been reported to cross the entire thickness of the retina [61, 62] , we expect the molecular size limit to be higher in unfixed tissue. More recently, Tao et al. concluded from similar experiments that the inner and outer nuclear layers are the predominant diffusional barriers (Fig. 3 ) [63] . These observations are based on free diffusion, active cellular transport of the drug (carrier) by a retinal cell type can ensure the distribution of macromolecules or drug carriers throughout the whole retina. Besides static hindering the diffusion of therapeutics, certain components within the retina might interact with subretinally injected therapeutics [64, 65] . Similar to the vitreous and the ILM, GAGs which are present in the interphotoreceptormatrix and on the surface of RPE cells, can bind therapeutic entities and in this way block their diffusion towards the target cells as suggested by Pitkänen et al. [50, 66] . In any case, the diffusional barrier can easily explain why gene expression after subretinal injection is more than often limited to the outer retina and RPE layer [67] . Clinical trials administering gene vectors by subretinal injection therefore mainly focus on diseases that have an initial causative mutation in the photoreceptors or RPE cells.
Barriers encountered after intravenous administration
Intravenous administration, or injection in the blood stream, is a widely applied administration route in the clinic (Fig. 1) , including in ophthalmology. A few examples of intravenously administered therapeutics for ocular diseases are anti-inflammatory drugs for uveitis [68] , antibiotics for endophthalmitis [68] and verteporfin for choroidal neovascularization [69] . While intravenous administration leaves the eye untouched and is therefore less invasive, the bioavailability of drugs in the retina after this type of administration is very low (b 5%) [70] . This is partly attributed to the marginal fraction of blood flow in the eye compared to the blood flow of other organs like the liver [27] . Intravenous injection therefore also requires higher volumes of the therapeutic to be administered to achieve therapeutic levels in the eye which inevitably raises the chance of unwanted off-target effects. Furthermore, it is well-established that the binding of serum proteins followed by recognition by the immune system can lead to rapid clearance of the therapeutics [71] . Nevertheless, researchers agree that there might be a future for ocular therapy via intravenous administration if efficient ocular targeting can be achieved. However, the efficient delivery in the eye of the therapeutic entity via the bloodstream is no guarantee for success. On the contrary, the presence of the blood-retinal barrier (BRB) within the eye signifies a major restriction for the permeation of compounds from the ocular blood flow into the retina [72] .
Blood-retinal barrier
The BRB contributes to the control of retinal homeostasis by tightly regulating the exchange of fluid and molecules between the blood and the retina and restricting the entry of hazardous macromolecules. This BRB support of retinal integrity is fundamental, which is illustrated by the fact that its breakdown is associated with vision loss [73] . The BRB is constituted of an inner (iBRB) and outer barrier (oBRB) represented by respectively the tight junctions of the inner retinal vasculature and the RPE cells in the outer retina (Fig. 3) . In the iBRB these tight junctions, also referred to as zonula occludens, are intertwined with adherens and gap junctions into sophisticated junction structures that strictly control paracellular transport [74] . Molecularly, intercellular junctions are constituted of a complex collection of proteins including occludin and claudin proteins [75] . On top of these junctions, also the transcellular transport of the iBRB is restricted thanks to the absence of fenestrations in the endothelial cells as well as the lack of transport vesicles. Together, these features result in a high transendothelial resistance which is comparable to that of the blood-brain-barrier [76] . Next to the primary role of endothelial cells in the iBRB, other retinal cell types also influence the barrier function. Surely, the basal lamina of endothelial cells are connected to the so-called neurovascular unit involving pericytes and glial cells like Müller cells and astrocytes. Whereas pericytes mainly influence the endothelial cells through the secretion of growth factors [77] , glial cells also offer support through the transfer of nutrients and waste products [74, 78] .
For therapeutics to reach the oBRB, they must first escape the choroidal blood flow. Conveniently, in contrast to capillaries of the inner vasculature, the endothelial cells of the choroidal capillaries are fenestrated allowing leakage of larger molecules like proteins [79, 80] . The choriocapillaries therefore represent no bottleneck for the systemic delivery of therapeutics into the eye [75] . Similarly, the Bruch's membrane, which lies in between the choroid and RPE layer, does not restrict macromolecular diffusion into the neuroretina [75] . The choroid-retinal transfer of macromolecules is in fact predominantly limited by the junctional complexes between the RPE cells. Similar to those of the iBRB, these complexes are constituted of an entanglement of tight, gap and adherens junctions [80] . In addition, the uneven distribution of RPE membrane proteins also adds to the function of the oBRB [75] . Fascinatingly, junctional complexes are not static structures yet their strands open and reseal to allow passage of molecules. Indeed, transfer of fluid and its components is limited yet elegantly regulated by several types of transport routes allowing the RPE to perform one of its primary functions i.e. preserving the ion, water and nutrient balance of the retina [81, 82] . Next to passive diffusion through the tight junctions, transport routes include active transport by pump proteins and transcytosis by means of invaginating vesicles [81] .
Seeing the strictly regulated transport of endogenous molecules across the BRB, it is not surprising the BRB represents a crucial hurdle for systemic delivery of foreign molecules in the retina. Initial studies with small hydrophilic molecules such as fluorescein have shown limited permeability of the oBRB, where inward diffusion (choroid to retina) is much lower than in the opposite direction [83] [84] [85] . It seems that sufficiently small solutes (b 0.4 nm) can diffuse freely through the pores of the junction network while the larger ones (N 0.4 nm) are dependent on the ability of the junctions to open and close [76] . A systematic study looking into the permeation of differently sized FITC-dextrans up to 80 kDa in isolated bovine RPE-choroid tissue also revealed that the permeability of macromolecules decreases dramatically with increasing size, with an insignificant permeability starting from 20 kDa [85] . Since the choroid poses no hurdle for permeation of the size ranges studied, it can be assumed the limitations observed are likely solely attributed to the RPE layer.
In addition to size, other physicochemical features of the entity such as charge and hydrophilicity influence to which extent the oBRB serves as a barrier [86] . The diffusion of ions, and likely therefore also of charged compounds, is hypothesized to be influenced by the charge features of the claudin proteins present in the junctions [76] . Pitkänen et al. tested the permeation of several similarly sized β-blockers in function of their lipophilicity and found that the more lipophilic ones crossed the oBRB substantially more efficiently [85] . Trends regarding physicochemistry of macromolecules that allow permeation of the iBRB are very similar, with hydrophilic substances again having great difficulty in overcoming this barrier [87] . Furthermore, Bellhorn et al. observed that dextrans as small as 3 kDa were unable of entering the retina through the oBRB nor the iBRB [88] . Generally, it is suggested that small hydrophilic compounds migrate through the paracellular network of junctions, while lipophilic molecules benefit from the transcellular route [85] . The iBRB and oBRB exhibit influx transporters for physiological substrates like the glucose transporter (GLUT) and L-type amino acid transporter (LAT). Designing drugs that resemble these transporter substrates could therefore be a strategy to enhance delivery across the BRB into the retina. Efflux pumps, on the other hand, work counteractive by shuttling the therapeutic back to the bloodstream [89] . The most well-known efflux pump is likely P-glycoprotein which is present on RPE cells as well as on the endothelial cells of the iBRB [90, 91] . Proposed strategies to prevent this shuttling are the design of therapeutics in such a way they are not recognized by efflux pumps, and/or the co-administration of efflux pump inhibitors (e.g. tariquidar or dexverapamil) [89, 92] .
Besides macromolecules, larger drug delivery vehicles like nanoparticles have also been evaluated on their ability to cross the BRB in vivoand intriguingly, with some success. In this regard, Kim et al. observed in mice that intravenously administrated gold nanoparticles of 100 nm were excluded while their smaller counterparts of 20 nm were present within the retina [93] . Similarly, AAV 9 vectors have also been reported to efficiently transduct the retina after systemic delivery, especially in the neonatal mouse with less developed vasculature [94, 95] . Seeing both particles are likely too large to passively diffuse through the junctional complexes, it is hypothesized that active processes such as transcytosis mediate their transport through the BRB [93] . Plasmid-loaded liposomes of greater size (~85 nm) are also reported to cross the BRB in mice, since gene expression was detected in the RPE as well as the inner retina. Interestingly, these liposomes were decorated with antibodies targeted against the transferrin receptor present in the BRB causing receptor-mediated transcytosis of the particles across the BRB into the retina [96] .
Similar as observed with the ILM, it is suggested that disease states associated with compromised BRB integrity might make systemic delivery of ocular therapeutics more feasible [74, 97, 98] . With this in mind, several strategies have been proposed to transiently manipulate the permeability of the BRB, such as the induction of ocular hypotony, treatment with vasoactive compounds or siRNA-mediated downregulation of tight junction proteins [72, 74, 99] .
Barriers encountered after suprachoroidal administration
Suprachoroidal administration involves injection into the suprachoroidal space (SCS), i.e. the virtual space between the sclera and the choroid (Fig. 1) . Under normal conditions this border is not an existent space, but can open up under the influence of the pressure applied by injection and incorporate fluid volumes up to 200 μl [97] . Strikingly, a study in ex vivo porcine eyes revealed that the injected material spreads out across the inner surface of the eye within 8 s [100] . Suprachoroidal administration also offers the advantage of bypassing several burdensome barriers present in other intraocular administration routes such as the ILM and the sclera, which often results in higher bioavailability in comparison to intravitreal injection and periocular administration, respectively [101] . There are several options to administer therapeutics into the SCS. The most promising concept currently investigated is likely the use of microneedles (maximum 1 mm in length), which might find its way to the clinic soon. These microneedles penetrate through the sclera to deliver into the SCS in a safe and minimally invasive way [102] [103] [104] . Suprachoroidal injection is rumored to be an ideal route to target the posterior segment. However, depending on the final target tissue several barriers should be taken into account. To reach the retina, both the RPE and the choroid should be successfully passed while for treatment of choroidal diseases (e.g. choroidal neovascularization) only the high choroidal circulation represents a potential hurdle [2, 105, 106] . Since the RPE has been extensively discussed in Section 2.3.1 we will focus here on the choroid.
Choroid
The choroid is the highly vascularized layer lying between the RPE layer and the sclera, with its primary function being the delivery of oxygen and nutrients from the blood flow into the outer retina. Other possible functions include the thermoregulation of the retina and assisting in focusing the eye [107] . The choroidal tissue is approximately 200 μm thick at birth and thins with age [108, 109] . Anatomically, the choroid is usually divided into five layers: the Bruch's membrane, the choriocapillary layer, two vascular layers and the suprachoroidea which is closest to the sclera (Fig. 4) [107] . The Bruch's membrane contains collagen and elastin and its inner and outer layer is represented by the basement membranes of the RPE cells and choriocapillaries, respectively [110] . The capillaries in the choriocapillary layer are highly fenestrated, allowing the passage of nutrients as well as larger molecules such as proteins [107] . The underlying vascular layers contain small arteries and increasingly larger blood vessels towards the sclera. Finally, the suprachoroid forms the border between the choroid and the sclera, and contains both collagen fibers and cell types from the stromal tissue such as melanocytes and fibroblasts [107] .
Technically, the choroid has two barrier roles. On the one hand it functions as a molecular sieve while on the other hand the choroidal blood flow functions as an important clearance mechanism. Naturally, the ability of certain therapeutics to reach their ocular targets will be defined by the ability to overcome both the static physical barrier as well as the dynamic barrier. Luckily, the barrier roles in relation to the physiochemical characteristics of the compounds are becoming increasingly clear.
The physical permeability of the choroidal tissue has been investigated with small molecules, macromolecules and particles. In case of small molecules, several groups found that injection of sodium fluorescein (NaF) and contrast agents into the SCS leads to the rapid spread of fluid around the SCS [100, 104, 111, 112] . Tyagi et al. found that the rate and level of delivery of NaF into the retina after suprachoroidal administration was higher when compared to periocular and intravitreal injection [111] . As expected, the diffusivity into the posterior segment depends on molecular weight. When FITC-dextrans with a molecular weight of 4 and 40 kDa were injected into the SCS of a rabbit ex vivo eye model, the delivery of the 4 kDa molecule in the vitreous and retina was substantially higher compared to its larger counterpart [112] . In the same report, also the permeability of various Beta-blockers with differing lipophilicity was evaluated. Higher lipophilicity correlated with increased choroidal and retinal delivery, most likely due to the interaction of lipophilic compounds to binding sites in the choroid and retina such as cellular membranes and melanin [113] .
The diffusivity of nano-and microparticles was tested ex vivo on porcine tissues [103] . After injecting particles into the SCS using a microneedle, 20 and 100 nm particles were found in the SCS as well as in the sclera, while 500 and 1000 nm particles could not diffuse into other tissues but the SCS. Strikingly, not only the physicochemistry of the therapeutic entity influences its bioavailability, also the injection site at which it is originally deposited can have an impact. In fact, Chiang et al. defined another anatomical barrier for the circumferential spread of particles across the SCS that was independent of the particle size, i.e. ciliary arteries. In rabbit eyes they observed that particles injected on one side of the posterior ciliary artery were unable of diffusing to its opposite side [115] .
An additional and likely greater hurdle than the static barrier function of the choroid is its circulation. It is established that the choroidal circulation is extraordinarily high when compared to other organs, to supply the high metabolic active RPE cells with the necessary oxygen and nutrients [101, 111] . Many groups have looked into the influence of choroidal circulation on the delivery of drugs in ocular tissues [97] . As a leading example, Abarca et al. demonstrated in ex vivo porcine eyes that the extent of delivery of a hydrophilic drug after suprachoroidal injection was higher in non-perfused eyes than perfused ones, while no difference was observed for a lipophilic dye. The choroidal circulation thus impedes effective drug delivery to the posterior segment, especially for hydrophilic compounds [116] . Many compounds such as fluorescently labeled dextrans of 40 and 250 kDa, bevacizumab and NaF have indeed been found to be rapidly cleared post-injection, usually within hours [97, 104, 111, 117] . In contrast, larger nondegradable particles of 20 nm up to 10 μm in size were detected in the SCS for two months [104] . This lack of clearance is in line with the predicted maximal pore size of the fenestrated choriocapillaries which is estimated to lie between 6 and 12 nm [118] . The above-mentioned observations indicate that sustained release systems such as nano-or microparticles can have great potential since their controlled delivery allows to compensate for the swift removal of the therapeutic [119, 120] .
Barriers encountered after transscleral administration
Transscleral drug delivery, often referred to as periocular drug delivery, is an umbrella term for different administration routes including subconjunctival, sub-tenon, peribulbar and retrobulbar routes (Fig. 1) . Since this review focuses primarily on barriers present at the back of the eye, we will not further discuss barriers specific to subconjunctival administration. The exact procedures and injection locations of these techniques are summarized in a review by Raghava et al. [121] . These type of injections, especially sub-tenon, are already applied in the clinic for e.g. applying local anaesthesia for ocular surgery [121] . The transscleral routes, which are less invasive than intravitreal injections, take advantage of the large surface area and permeability of the sclera [122, 123] . Furthermore, relatively large volumes can be administered with a single injection, with up to 4 ml and 5 ml for sub-tenon and retrobulbar injection, respectively [121] . The periocular route is definitely a valuable one for treatment of diseases of the middle and outer coat of the eye. Its potential for treating retinal diseases is, however, still a matter of debate, as therapeutic concentrations within the retina remain quite low [124] . Therapeutics should indeed overcome static barriers such as the sclera, choroid and the RPE layer, whilst also encountering dynamic barriers like choroidal blood flow and episcleral flow [123, 125] . Since all these barriers interact with each other it is troublesome to define the relative role of each one, especially since the barrier function also depends on the properties of the drug [123] . It is in fact the combination of the various barriers involved that makes periocular delivery a challenge. Since the RPE layer and choroid are already extensively discussed in Sections 2.3.1 and 2.4.1 respectively, we limit our focus in this section on the sclera.
Sclera
The sclera or the white of the eye is the outer opaque layer of the ocular globe that blends into the transparent cornea at the front of the eye. The opacity of the sclera is no coincidence since it prevents internal light scattering which ensures an optimal retinal image [126] . The human scleral thickness is not consistent but averages around 0.5 mm at the limbus to approximately 1 mm at the optic nerve [126, 127] . The sclera has several mechanical functions such as general support of the eye, maintaining the shape of the eye during its movement and protecting the eye against external injuries as well as increased internal ocular pressures [127, 128] .
Microscopically, several regions can be differentiated from the outside to the inner side of the sclera (Fig. 4) , including the episclera, the stromal tissue and the lamina fusca [126] . On a molecular level, the sclera is built up from the typical components of connective tissue i.e. collagen, proteoglycans and glycoproteins. The predominant structural protein, collagen type I, forms fibers and fiber bundles with varying thickness and orientation depending on the region and tissue depth [127] . In the episclera, a thin vascularized layer, the collagen fibers connect to the blood vessel walls or the underlying stromal tissue [126] . The outer regions of the stromal tissue contain thinner bundles with lamellar characteristics, while their counterparts in the inner layers of the stroma are generally thicker and orientated in a multitude of directions [127] . Finally, the collagen bundles of the lamina fusca are smaller and strongly intertwine to integrate into the choroidal layer below [126] . Remarkably, similar to the sclera, the corneal tissue is also based on collagen fibers, yet the cornea has a highly transparent appearance. This contrast in opacity can be explained by the different ultrastructure of the two tissues: while the collagen fibers of the sclera are quite thick and compactly organized, their corneal counterparts are thinner, strictly longitudinally oriented and more widely separated [130] . Next to collagen fibrils also a small fraction of elastic fibers runs through the scleral tissue which adds to the viscoelastic properties of the tissue [131] . Notably, the sclera is not acellular but contains fibroblasts responsible for the synthesis and turnover of the scleral matrix [131] .
The permeability of the sclera and its barrier role has been extensively described in literature in context of a wide range of compounds ranging from antibiotics to dextrans [125] . Considering the dense structure of the sclera, it represents a physical barrier towards many therapeutics. Successful passage through the complex fiber network has proven to be highly dependent on the molecular weight of the compound, where larger molecules have more trouble diffusing than smaller ones (up to 150 kDa) [123, [132] [133] [134] [135] [136] . On the other hand, clearance values for macromolecules are much lower than for smaller molecules [123] . Apart from molecular weight, Ambati et al. revealed that molecular radius is an even better predictor of permeability, as globular proteins permeated faster through the sclera than linear dextrans with similar molecular weight [133] . Still, the same molecular radius does not necessarily result in similar permeability coefficients. In fact, Cheruvu et al. found that negatively charged solutes permeated across the sclera more effectively than positively charged ones despite their comparable radii [113] . This is a logic consequence of the matrix structure seeing the sclera contains proteoglycans that are negatively charged at physiological pH [137] . Too many negative charges on macromolecules, on the other hand, might also inhibit permeation due to charge repulsion [123] . Next to size and charge also lipophilicity has an influence on scleral permeation, where hydrophilic molecules more readily diffuse through the sclera than lipophilic ones as observed in scleral tissue of multiple species [86, 113, 125, 138] . This is likely due to the aqueous nature of the sclera owing to the hydrated proteoglycans [125] . Importantly, choroidal bioavailability is often also low for hydrophilic molecules, since the largest part of the drug eventually reaching the choroid is likely next cleared by the choroidal blood flow [125] .
Regarding nano-and microparticles, there are only limited reports on penetration of ocular tissues after periocular administration. Amrite et al. looked into the influence of particle size on the retention at the injection site by comparing the disposition of 20 nm, 200 nm and 2 μm sized polystyrene particles in vivo in rats. Except for a very limited amount of 20 nm particles, no particles were present in the ocular tissues after injection [139, 140] . Additionally, 20 nm but not larger particles were rapidly cleared from the injection site, with only 15% remaining one day post-administration [139] . Also in bovine ex vivo experiments only 0.46% of the 20 nm particles were able to cross the sclera [140] . Successful delivery of particles to the ocular tissues after periocular administration is therefore dependent on a challenging balance. While smaller particles can penetrate into ocular tissues but are cleared rapidly from the injection site, larger particles are retained but are unable of reaching the retina. Drug delivery strategies concentrating on nano-and microparticles therefore tend to focus on particles as vehicles for sustained delivery [2, 121, 142] . Besides from the particles delivered, research groups also look into clever modifications of the technique by which it is delivered, like the application of hollow microneedles penetrating into the sclera [143] .
In all cases, it should be noted that the scleral thickness can differ greatly among species [132] , which has a direct impact on the permeability of the sclera. In light of this, the study of Nicoli et al. serves as a leading example: they found porcine sclera to be twice as thick as human sclera which reflected in the fact that in comparison the permeability of human sclera was up to three times higher [145] . In contrast, the rabbit sclera is approximately twice as thin as the human sclera which yet again should be taken into account when extrapolating results based on this species to the human situation [132] . Similar to the other structures of the eye, aging also affects the sclera which yet again can influence its permeability. Indeed, it has been reported that the hydration of the sclera decreases with age and seeing permeability declines with decreasing hydration this can certainly have an impact on drug distribution [135, 146] . The age of the animals used during sclera permeation studies is therefore a factor than can add to experimental variability.
3.
In vitro and ex vivo methods to study barrier roles 3.1. Barrier-specific methods
Methods to study the vitreous
Over the last two decades several methods have been developed to improve our understanding of the vitreous structure and the behavior of therapeutics within it, ranging from rather straightforward in vitro methods to more relevant though more complex ex vivo techniques. This is likely owing to the advancement of technology in general combined with the integration of the 3R principle regarding animal experiments (reduction, refinement and replacement) [142] .
Prior to starting experiments on vitreous, it is important to note that the vitreous structure varies across different species [10] . For example, it is estimated that the collagen content is up to five times lower in bovine vitreous compared to its human counterpart [8] . These species-specific variations should be taken into account since the impact of the vitreous as a barrier could be over-or underestimated in comparison with the human situation [10] . Overall, large animal models such as cow, pig and non-human primates are significantly more representative for the human vitreous structure. Seeing the small volume of vitreous present in the mouse eye, vitreous isolation and quantification of its components is troublesome [147] . Hence, the composition of mouse vitreous is less documented and it is unclear if mice are relevant animal models to test the in vivo potential of a drug delivery system. Notably, even within one species the structure of the vitreous can vary: it is well established that the vitreous gel loses its gel-like appearance and liquefies with age. This implies that the migration of therapeutics towards the retina could also be age-dependent [11] .
The most straightforward in vitro experiments to study the barrier role of vitreous, involve the removal of vitreous from the eye. In the earliest experiments, diffusivity of a fluorescent dye such as fluorescein was measured in the isolated vitreous (often bovine) based on the concentrations measured with a fluorometer [24, 148, 149] . While most of these studies only considered passive diffusion, Xu et al. included the influence of convection by applying a custom-built diffusion cell and numerical modeling [24] . To investigate the barrier role of vitreous for larger structures, like nanoparticles, the use of fluorescence microscopy to evaluate binding of (fluorescent) nanoparticles to vitreous components could be a first preliminary experiment. For more accurate interpretations, the diffusion of fluorescent small molecules as well as nanoparticles in isolated vitreous can also be assessed by Fluorescence Recovery After Photobleaching (FRAP). In this microscopy technique, fluorescent components are permanently bleached in a small area of the vitreous by a high intensity laser. Next, diffusion of surrounding fluorescent molecules into the bleached area causes the recovery of fluorescence, which is measured over time using a low intensity laser. Based on the fluorescence recovery, the diffusion coefficient and fraction of (im)mobile molecules can be precisely calculated [15, 23] .
Isolated vitreous can also be used in cell culture experiments. Pitkänen et al., for example, applied a thin layer of freshly isolated bovine vitreous on top of an RPE cell culture after which DNA-complexes were supplemented on top. The following transfection and uptake studies revealed that the presence of vitreous nearly entirely blocked particle uptake and thus gene transfer [13] . Since these in vitro methods are very straightforward, they are certainly valuable for providing a first impression whether or not the vitreous hampers the efficiency of a certain therapeutic. However, it is well-known that without the support of the eye the vitreous loses its typical structure due to outflow of hyaluronic acid [150] . Therefore, tests on isolated vitreous could lead to biased results which is the principal limitation of these in vitro methods. Ex vivo methods on the other hand, are usually more representative for the in vivo tissue structures as the vitreous is (partially) maintained in its natural environment.
The ex vivo models of Martens et al. and Xu et al. are ideally suited for studying the drug delivery of larger entities like viral or non-viral gene carriers [17, 22, 151] . Both models share the same principle: fluorescent nanoparticles are injected in the vitreous of a cadaveric cow eye after which their diffusion is followed by particle tracking microscopy. Tracking each particle in function of time allows to calculate a distribution of diffusion coefficients that is highly representative for the Brownian motion taking place. Though both models are quite similar, the dissection and subsequent set-up are slightly different: while Xu et al. disposes the entire anterior part of the eye resulting in an eye-cup and exposure of the vitreous, Martens et al. only removes the cornea and lens so that the hyaloid membrane and the rest of the eye remains intact. In the latter model, particles are therefore allowed to diffuse for 24 h instead of less than an hour in the exposed vitreous. On the other hand, in the system of Martens et al. nanoparticles are intravitreally injected unusually close to the hyaloid membrane owing to working distance limitations of the objective lens needed for single particle tracking [151] . Xu et al., in contrast, injects the nanoparticle suspension in the central vitreous, which is likely more representative for the intravitreal injections taking place in the clinic [17] . All these ex vivo methods are though less straightforward, highly relevant for drug delivery studies since they allow us to study the static barrier functions of tissues from larger more representative animals, without proceeding to costly and often unnecessary in vivo experiments. It is important to recognize, however, that information on the influence of dynamic barrier roles such as for example the anteriorposterior convective flow, is lost. Furthermore, the above-mentioned assays do not take into account the potential influence of vitreous humor motion during eye rotations on the dispersion of therapeutics in the vitreous [28] . To look into these factors affecting the delivery of a drug (vehicle), in vivo studies are still unique and necessary.
Methods to study the blood-retinal barrier
Studies with the goal to investigate the potential of therapeutics to permeate the BRB can be roughly subdivided in two categories: in vitro studies based on endothelial or epithelial cell cultures, and ex vivo studies based on isolated RPE/choroid tissue in diffusion chambers (discussed in Section 3.2.2.). The most straightforward and thus most applied in vitro experimental set-up involves the culture of BRB cell types on specialized filter systems of which the most frequently used is the Transwell system. These filters can be coated with e.g. laminin and/or fibronectin to mimic extracellular matrices and allow cells to grow in a polarized fashion [152] . The permeability of macromolecules through the iBRB or oBRB can then be evaluated in vitro by quantifying the fraction of macromolecules, applied at the apical side, that crossed the BRB and reached the basal medium at specific time points. This quantification can be done by a diversity of methods ranging from fluorescence measurements with a plate reader to mass spectrometry [153] [154] [155] [156] [157] . Naturally, the permeability of the compounds through the blank filter system should also be determined to account for potential barrier properties of the filter itself [153] .
These in vitro barrier studies can be performed on immortalized cell lines or primary cultures, where both options have their merits and disadvantages. Whereas cell lines are straightforward to culture and store, and allow comparison of test results between different research groups, they are often not truly representative of the in vivo setting, especially when it comes to barrier function [76] . Employing primary cultures, on the other hand, can be troublesome in practical terms owing to complex isolation protocols. Moreover, the isolated cell population is often more heterogeneous which complicates the interpretation of results [153] . Nevertheless, these cultures are regarded as more representative. It should be noted that finding cell culture conditions that result in the most representative phenotype is known to be a universal challenge [76, 158] . Indeed, culture conditions can greatly influence the characteristics of e.g. the RPE layer, which might have an impact on its barrier function. In fact, it is well established that the RPE layer exhibits variations related to species and age, which implies that when working with primary cell cultures animals should be carefully selected [76] . It has furthermore been reported that even within the same RPE layer microenvironments can be distinguished, which can further add to tissue variability [159] . A critical review on the culture options for RPE and influence of culture conditions on its properties has been published recently by Rizzolo et al. [76] .
Recently, several groups have made progress in the development of more advanced co-cultures of multiple BRB cell types [155] [156] [157] [158] [159] [160] [161] . An elegant example of this is the work of Wisniewska-Kruk et al. who managed to mimic the iBRB by co-culture of primary endothelial cells, pericytes and astrocytes. In brief, they allowed pericytes and astrocytes to adhere to the bottom of the Transwell filter after which endothelial cells were cultured on top of the filter. After a few days of culture, permeability studies were performed as usual: fluorescent dextrans and other tracers were added to the top compartment after which their presence in the bottom compartment was measured [155] . The further in vitro finetuning of co-cultures is expected to increasingly mimic the barrier role of the BRB in vivo.
General methods for barrier investigation
Retinal explants
The culture of retinal explants is a widely applied method in a variety of ocular studies, especially in fundamental research and retinal drug delivery. Similar to polarized ocular cell types, explants are typically cultured on specialized membranes (e.g. Transwell filters) that allow to add substances below the filter and/or on top of the explant. Except for the commercially available filter systems, this experimental set-up does not require special equipment and is therefore readily accessible for each research group.
Retinal explant culture can help to define to which extent the neural retina or ILM represents a barrier to the diffusion of therapeutics. Interestingly, the orientation of the explant, i.e. photoreceptor-side up or down, can be altered depending on the research question investigated [67, 163] . To investigate the penetration of intravitreal injected therapeutics into the retina, isolated explants are typically cultured with photoreceptor-side down. Even when detaching the vitreous from the retina while dissecting, the ILM usually remains largely intact, especially in larger species such as cow or human. Therefore, therapeutics or drug carriers can be dropped on top of the explant, to follow transfer through the ILM into the retina. When looking into subretinal injection there are generally two options: therapeutic entities are applied directly on top of the retinal explants (photoreceptor side upwards) on a Transwell insert [67] , or the therapeutic entities are placed on the filter and covered with the retinal explants (photoreceptor side down) [163] . After a certain time point (e.g. 24 h), the penetration of the entity can then be examined by microscopy after preparing cryosections. It should be noted, however, that it is always important to prevent overflow to the other side of the retina when applying a larger volume of therapeutics on top of the retina, since this can result in biased interpretations.
Our research group recently developed an ex vivo explant model, based on bovine eyes, in which the vitreous remains attached to the ILM and retina at all times ensuring an intact vitreoretinal interface. After dissection and explant culture, fluorescent therapeutics or drug carriers can be injected intravitreally to determine the extent and route of retinal penetration using two imaging techniques. The first method uses a water-dipping objective, pushed gently on top of the vitreous, which allows to image horizontal sections of the retina with a confocal microscope. Secondly, as with all explants, cryosections can be made which allows to vertically image all retinal layers at the same time, combined with (immuno)staining for various retinal structures [178] .
Diffusion chambers
While the retinal explants described above allow for valuable estimations of the extent and relative rate at which certain entities penetrate into the retina, studies performed using a diffusion chamber can provide us with accurate absolute diffusional rates. The Ussing chamber, originally developed to look into ion transport across epithelial membranes, has led to the advancement of the understanding of transport of molecules through tissues in many fields including the ocular one [164, 165] . In this Ussing chamber system, the studied tissue is mounted in such a way that it forms the physical barrier between two halves of one chamber. One of these halves contains the tested compound, while the second half merely contains a buffer with the same osmolarity and if necessary, antibiotics. After a certain time point (e.g. 24 h) the rate of diffusion through the tissue can be measured by detecting the compound in the opposite half with for example a spectrophotometer. To monitor the viability and integrity of the studied barrier during these experiments the transepithelial electrical resistance (TEER) can be assessed. This resistance can be measured in an non-invasive way by placing an electrode pair in both halves of the Ussing chamber that can detect voltage and current [74, 86, 166] . Next to these quantitative measurements, the location of the compounds within the tissue can be examined after the conventional cryosection protocol followed by microscopy. The Ussing diffusion chamber and its variations can be used to study almost every barrier discussed in this review. In fact, studies applying a diffusion chamber have been reported on the ILM [60] , retinal tissue [60, 63] , the oBRB [84, 85, 167] , the choroid [113] , and the sclera [113, 140, 168] . The application of a diffusion chamber indeed offers several advantages. For instance, depending on the barrier you aim to investigate a certain side of the tissue can be directed towards the donor or the receiver chamber. As with the retinal explants described above, changing the orientation of the retina towards the donor chamber for example allows you to focus on the ILM or the photoreceptor layer [60] . In case of transscleral administration for retinal targets, a diffusion chamber allows to define for your compound which physical barrier signifies the dominant hurdle (the choroid or the sclera) simply by mounting scleral tissue with and without choroid in the chamber [113] .
While these experiments can provide us with highly valuable qualitative and quantitative information, certainly for diffusion of macromolecules, they are less accessible since they require uncommon instrumentation that might not be available in every research group. It should also be noted that while the Ussing chamber is a commercially available diffusion system, some groups apply the same principle but make use of a custom-designed set-up [63] .
Perfused eye models
Originally developed in the early 80s for biological studies, the isolated perfused eye model has been optimized in multiple species over the years ranging from cat to human while focus has also switched towards drug delivery [170] [171] [172] [173] [174] [175] . In this technique, an entire mammalian eye is isolated after which a ciliary artery is cannulated to supply it with carefully composed perfusion fluid. By means of a peristaltic pump, the eye is then perfused while keeping it moist. Next, pharmacokinetic and drug distribution studies following administration of a therapeutic can be performed by quantification of the therapeutic in the different ocular tissues using mass spectrometry or fluorometry. Many drug delivery studies have already been done based on this model, usually focusing on intravitreal [173, 174, 176] , or suprachoroidal drug delivery [103, 112, 116] . Patel et al. added an interesting feature to the common ex vivo eye model by inserting a cannula connected to an irrigating solution through the optic nerve into the vitreous [103] . In this fashion, they mimicked an elevated intraocular pressure and evaluated the effect on particle delivery by hollow microneedles.
The level and approximate location of fluorescence can also be detected noninvasively by making use of an ocular fluorometer like the Fluorotron [112, 136] , which can also be applied in vivo [104, 112] . With this technique the fluorescence levels are determined following a straight axis along the entire eye, where the measurement distance is correlated with specific layers within the eye, such as the vitreous, the choroid/retina and the sclera. A downside of this technique is that it does not provide the precise location of the fluorescent compounds in these tissues. The choroid and retina, for example, are so close to each other it is not feasible to estimate the fluorescence in these layers separately. Naturally, histological examinations of tissue sections can still be performed to resolve these issues.
Well-established advantages of this system over in vivo experiments are among others: no influence of anesthesia, no limitation on applied drug concentration and complete control over physiological environment while reducing animal usage [174] . Thanks to the perfusion, the model also allows to look into the influence of clearance mechanisms, like the choroidal circulation, on drug delivery [116] . Nevertheless, it remains a great difficulty to fully mimic the remarkably complex in vivo conditions. In addition, viability of the full ex vivo eye is limited to around 9 h which can form a limitation when aiming for pharmacokinetics focusing on longer timepoints [173, 177] .
Conclusion
In the past decade, a lot of effort of industry and academia has gone to the design of new drug delivery vehicles and advanced administration techniques to treat blinding diseases that find their origin at the back of the eye. Nevertheless, despite this effort and the resulting progress therapeutic efficacy remains limited, especially in case of larger entities such as nucleic acids. This inefficient delivery of therapeutics is usually due to the many physiological barriers encountered by the therapeutic entity. Each administration route to target the posterior segment has it specific barriers, benefits and disadvantages (Fig. 1) . For example, Table 1 Overview Size Mesh size~550 nm [17] 1 μm particles were mobile in vitreous [14] Mesh size~10 to 25 nm [49] 350 nm particles and 2000 kDa dextran crossed ILM [16, 48, 50] Free diffusion is limited to b76 kDa in fixed human retina [59] Active cellular transport can shuttle larger entities through retina Solutes b0.4 nm can freely diffuse through BRB [71] Very low permeability above 20 kDa [80] 20 nm gold particles and 85 nm targeted liposomes crossed BRB [90, 91] 40 kDa dextran crossed choroid [107] 20 nm particles delivered in SCS did not reach retina [100] 150 kDa, possibly higher diffuses through sclera [160] Barely penetration of 20 nm polystyrene particles through sclera [133] Charge Negative, [18] [19] [20] [21] Neutral to negative [16, 21, 49, 50] Negative, [48, 63] N.D.
N.D.
Negative, [108] Hydrophilicity Hydrophilic compounds have longer half-lives [27] N.D. likely hydrophilic
N.D. likely lipophilic
Lipophilic [80, 82] Lipophilic [107] Hydrophilic [81, 108, 118, 130] Other features Coating particles with polymers like PEG or HA can increase diffusion [15, 22, 23] Binding to ligands at the ILM influences viral vector passage through the ILM [42, 43, [45] [46] [47] Targeting for receptors present in BRB cells can facilitate BRB passage [91] while subretinal injection theoretically involves the least barriers, it is at the same time a highly invasive technique. Intravitreal injection, on the other hand, is a highly safe and feasible administration method, but comes with challenging drug delivery barriers such as the vitreous and the ILM. The balance between efficacy and safety therefore remains difficult to maintain. Interestingly, the ideal physicochemical characteristics of a therapeutic (carrier) depends on the barrier it needs to overcome and therefore also on the preferred administration route ( Table 1) . The sclera and vitreous are for example more permeable for hydrophilic compounds while the choroid and retina are easier to cross for lipophilic ones. In view of the complexity of the various barriers we encourage drug delivery researchers to systematically explore which physicochemistry (e.g. size, charge and hydrophilicity/hydrophobicity) a therapeutic needs to surmount every barrier of importance for the chosen delivery route. To perform these studies, a whole variety of in vitro and ex vivo methods are available. In vitro studies on ocular cell cultures can be powerful to provide preliminary results on the intrinsic therapeutic potential of new compounds and to evaluate if the vitreous represents an obstacle for transfection. In addition, intelligently designed ex vivo experiments can be as valuable as in vivo studies -if not more. Indeed, ex vivo studies, which are in line with the worldwide resolution to implement the 3R principle, allow to look into tissues of larger animals that have a physiology resembling the human one. It is expected that the increasing knowledge of the exact barrier composition, and especially, the interspecies variability will help to further define which model is most related to the complex in vivo human situation by preventing over-or underestimation of species-dependent barrier functions. Finally, it is well established that age and disease can affect the composition and/or the integrity of nearly each barrier discussed in this review. Therefore, the development of standardized in vitro and ex vivo disease models next to the existing in vivo ones could be an important field of research to evaluate the delivery of drugs and carriers to diseased or aged tissues. Overall, we are confident that the increasing barrier knowledge and the proper use of in vitro and ex vivo methods will continue to boost the design and optimization of drug delivery systems that are successful in treating disease targets at the back of the eye.
